Point Medical, Dijon

Ezetimibe with simvastatin treatment enabled more patients to reach LDL-C target

Published in Elder Law Weekly, September 14th, 2005

Researchers have investigated the effect of coadministering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.

Researchers in France conducted a study "to determine whether coadministering ezetimibe with on-going simvastatin treatment was more effective than placebo plus ongoing simvastatin in achieving an LDL-C treatment target of {{<=}}2.60 mmol/l (100 mg/dl) in hypercholesterolemic patients with coronary heart disease (CHD)."

M. Farnier and colleagues of Point Medical in Dijon explained, "Men and women (age {{>=}}18 years) with documented CHD and on a stable...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Elder Law Weekly

Source: Elder Law Weekly (2005-09-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry